Royalty Pharma (RPRX)
Health Care · Alternative Asset Management / Specialty Finance · NASDAQ
Royalty Pharma is the leading acquirer of biopharmaceutical royalties, providing capital to fund medical innovation in exchange for long-term revenue streams from successful therapeutic products.
What Royalty Pharma does
Royalty Pharma is a large-scale buyer of biopharmaceutical royalties, which acquires royalty interests in commercialized and development-stage medicines from academic institutions, research hospitals, non-profits, and biopharmaceutical companies. The company does not conduct internal drug development, instead acting as a capital provider that funds innovation in exchange for future revenue streams from life-science products. Its business model relies on acquiring and managing a diverse portfolio of royalty interests across various therapeutic areas.
Themes: biopharmaceutical innovation funding, life science royalties, alternative asset management, healthcare capital deployment
Fundamentals
- Price$61.31 as of 2026-08-21 close
- Market cap$23.8B as of 2026-08-21
- 1-year return+68.9% 2025-08-21 close $36.31 → 2026-08-21 close $61.31
- P/E41.11 as of 2026-08-24
- Net margin+32.1% as of 2026-08-24
- ROE+12.3% as of 2026-08-24
- Debt / equity1.31 as of 2026-08-24
- Revenue growth (YoY)+10.0% as of 2026-08-24
- Revenue CAGR (3y)+2.1% SEC XBRL
- Beta0.41 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +3.0%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How RPRX compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
RPRX is in the Health Care Long-term Top 10.
Health Care Long-term Top 10 — since 18 Aug 2026
Long-term score
61.6 #144 of 987 scored · #7 of 57 in Health Care
Long-term trend 90th (it is 1.3% below its highest point of the past year) and capital return 71st (consecutive years of dividend increases 5 years); weakest is valuation (31st, price to earnings 42, price to book 3.4).
Short-term score
64.9 #54 of 1,704 scored · #20 of 240 in Health Care
Catalysts 85th: the analyst consensus rating has improved toward "buy" since the prior reading; trend 78th: a "golden cross" — its 50-day average is above its 200-day; weakest is setup 47th: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 2% of it.
In this list since 18 Aug 2026 — currently 7th in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 8, score 57.2.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Royalty Pharma looks technically
Royalty Pharma (RPRX) is trading 28.0% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 387 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 1.3% below its all-time high.
Trend
8
| Distance from the 200-day | it is trading 28.0% above its 200-day average, the long-term trend line — a longer-term uptrend | +28.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $57.35 | $57.35 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $47.91 | $47.91 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 56.36. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 387 trading days ago — a "golden cross", a bullish long-term signal | 387 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend) | 24.9 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($56.36 to $62.10) — its "stochastic" reading is 86 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 86.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 5 trading days ago (its momentum flipped positive) | 5 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $62.10 | $62.10 |
|---|---|---|
| From the 52-week high | it is 1.3% below its 52-week high (its highest price of the past year) | -1.3% |
| Above the 52-week low | it is 79.9% above its 52-week low (its lowest price of the past year) | +79.9% |
| Below the 52-week high | it is 1.3% below its highest point of the past year | 1.3% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $62.10 (set on 2026-08-20) | $62.10 |
| Given back of the 52-week move | over the past year its closes ranged ($34.90 to $61.73), and it has given back essentially none of its rise from last year’s low — 2% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $44.29 to $45.15. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.6% |
| From the all-time high | it is 1.3% below its all-time high | -1.3% |
| Nearest price level | it is trading 8.2% above a support level at $56.31 — a price it turned at three times since 2026-05-29, most recently on 2026-08-04. Since 2024-08-21 it has 13 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -8.2% |
| All-time low | its lowest closing price on record is $24.05 (set on 2024-12-19) | $24.05 |
| Above the all-time low | it is 154.9% above its all-time low | +154.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 62nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.42 between its high and its low — about 2.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.42 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $56.19 and $61.48 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $56.19 – $58.83 – $61.48 |
| Typical daily range (% of price) | its price moves about 2.3% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.3% |
| Stretch from the 200-day average | it is trading 9.4 daily ranges above its 200-day average price (28.0% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 9.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.84× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.6% since the prior reading | +1.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.17 toward buy |
Candlestick patterns
2
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 7 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 7 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.1% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-08-06 has been "filled" 11 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 11 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 2.6 percentage points (the stock gained 4.9% while the market gained 2.3%) | +2.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 11.4 percentage points (the stock gained 14.5% while the market gained 3.1%) | +11.4% |
| vs market, 6 months | over the past 6 months this stock beat the market by 24.8 percentage points (the stock gained 35.9% while the market gained 11.1%) | +24.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 48.4 percentage points (the stock gained 68.9% while the market gained 20.5%) | +48.4% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.6% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 3.2% of the share price. | +9.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 22% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $50.07 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +22.4% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $58.88 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +4.1% |
Price levels it has turned at before
RPRX last closed at $61.31 on 2026-08-21. Since 2024-08-21 it has turned at 13 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $56.31 | Support | 8.2% below the last close | turned there three times · 2026-05-29 to 2026-08-04 |
| $49.09 | Support | 19.9% below the last close | turned there twice · 2026-04-02 to 2026-05-04 |
| $44.84 | Support | 26.9% below the last close | turned there twice · 2026-03-06 to 2026-03-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $56.36.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $61.85 and $65.24 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $56.36.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · Analyst price target recently RAISED · Near the all-time high | Learn: moving average · golden cross · adx · rsi · macd · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$64.75 range $61.00 – $70.00; median $65.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for RPRX
- Consensus EPS estimate$1.17 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Risks associated with the commercial success and sales performance of biopharmaceutical products on which the company receives royalties.","Dependency on third-party marketers and developers who control the commercialization and development of the underlying products.","Uncertainty in the royalty market, including the availability of attractive acquisition opportunities and increased competition for capital deployment."]
What changed in the latest 10-Q
AI-assisted comparison of RPRX's 10-Q filed 2026-05-06 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Reworded:
- Reference to annual report changed from '2024 Annual Report on Form 10-K' (filed 2025-11-05) to '2025 Annual Report on Form 10-K' (filed 2026-05-06)
- Notes:
- Both text excerpts are truncated at the same point ('and in Part II,'); comparison is limited to the available portion
Risk Factors
- Added:
- Added to bullet point list under 'Risks Relating to Our Business' (filed 2026-05-06): 'our ability to generate increasing royalty receipts and to achieve attractive returns on our investments, including maintaining attractive internal rates of return and consistent returns on invested capital and returns on invested equity;'
- Added to bullet point list under 'Risks Relating to Our Business' (filed 2026-05-06): 'potential strategic acquisitions of operating biopharmaceutical companies;' (changed from 'potential strategic acquisitions of biopharmaceutical companies;')
- Added language to 'Biopharmaceutical products are subject to sales risks' section (filed 2026-05-06): 'delays or failures in obtaining marketing approval in one or more jurisdictions or for additional product indications' and 'changes in the marketer's strategic priorities, obsolescence, lack of coverage or insufficient reimbursement by healthcare programs or insurance plans' with expanded detail on reimbursement
- Added language to 'Biopharmaceutical products are subject to sales risks' section (filed 2026-05-06): reference to 'internal rates of return, returns on invested capital and returns on invested equity' in context of royalty payment impacts
- Added to 'General Risk Factors' (filed 2026-05-06): 'data breaches' added to cyber-attack risk description; removed reference to 'the outbreak of any infectious or contagious diseases'
- Removed:
- Removed from bullet point list under 'Risks Relating to Our Business' (older filing 2025-11-05): 'the growth of the royalty market;' and replaced with 'risks related to the growth and dynamics of the royalty market;'
- Removed from bullet point list under 'Risks Relating to Our Business' (older filing 2025-11-05): 'uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy to add interests in development-stage product candidates to our product portfolio;' and replaced with shorter version 'uncertainties related to acquiring interests in development-stage biopharmaceutical product candidates;'
- Removed from bullet point list under 'Risks Relating to Our Business' (older filing 2025-11-05): 'marketers of products that generate our royalties are outside of our control and are responsible for development, pursuit of ongoing regulatory approval, commercialization, manufacturing and marketing;' and replaced with 'marketers of products that generate our royalties are outside of our control;'
- Removed from bullet point under 'Risks Relating to Our Organization and Structure' (older filing 2025-11-05): 'we may not realize the anticipated benefits of the Internalization and we may be exposed to risks to which we have not historically been exposed;' and replaced with 'we may not realize the anticipated benefits of the Internalization and we may be exposed to new risks and costs;'
- Removed from 'General Risk Factors' (older filing 2025-11-05): 'the outbreak of any infectious or contagious diseases.'
- Removed from 'Acquisitions of royalties' section (older filing 2025-11-05): 'We may acquire more royalties on development-stage product candidates' changed to 'We acquire royalties on development-stage product candidates'
- Removed from 'Acquisitions of royalties' section (older filing 2025-11-05): 'European Medicines Agency' reference changed to 'EMA' with parenthetical abbreviation in newer filing
- Removed from 'Acquisitions of royalties' section (older filing 2025-11-05): phrase 'restrictions on the marketing of the product and could include withdrawal' changed to 'marketing restrictions or withdrawal' in newer filing
- Reworded:
- Changed bullet point wording from 'risks related to sales of biopharmaceutical products on which we receive royalties;' to same in both filings (no change)
- Changed 'the growth of the royalty market;' to 'risks related to the growth and dynamics of the royalty market;' (filed 2026-05-06)
- Changed 'uncertainties related to the acquisition of interests...' to 'uncertainties related to acquiring interests...' and removed reference to strategy to add interests to portfolio (filed 2026-05-06)
- Condensed bullet point about marketers' responsibilities by removing specific functions listed (filed 2026-05-06)
- Changed 'we may be exposed to risks to which we have not historically been exposed;' to 'we may be exposed to new risks and costs;' (filed 2026-05-06)
- Changed 'cyber-attacks or other failures in telecommunications or information technology systems' to 'cyber-attacks, data breaches or other failures in information technology systems' (filed 2026-05-06)
- Changed 'Biopharmaceutical product sales may be lower than expected due to a number of reasons, including...' with additions of specific approval/indication delays and expanded reimbursement language (filed 2026-05-06)
- Changed 'lack of acceptance by healthcare programs or insurance plans' to 'lack of coverage or insufficient reimbursement by healthcare programs or insurance plans' (filed 2026-05-06)
- Changed 'We have been able to grow our business over time' to 'We have historically grown our business' (filed 2026-05-06)
- Changed 'invest the full amount of capital that may be available to us in the future, or at our targeted amount and rate of capital deployment' to 'invest the capital available to us at our targeted rate of capital deployment' (filed 2026-05-06)
- Changed 'for a period of several years' to 'for several years' (filed 2026-05-06)
- Changed 'We may acquire more royalties on development-stage product candidates' to 'We acquire royalties on development-stage product candidates' (filed 2026-05-06)
- Changed reference from 'the European Medicines Agency ("EMA")' to 'the EMA' with parenthetical at first full mention (filed 2026-05-06)
- Changed 'or that the market will be receptive to such products' to include pricing and reimbursement consideration (filed 2026-05-06)
- Changed 'restrictions on the marketing of the product and could include withdrawal of the product from the market' to 'marketing restrictions or withdrawal from the market' (filed 2026-05-06)
- Notes:
- The newer filing text appears truncated at the end ('which will result in a loss for us. Losses from such assets could adversely affect our business, financia'), making complete assessment of remaining sections uncertain
- The older filing text is also truncated ('We intend to continue to provide capital to innovators to co-fund clinical development of a product candidate in exchange for a share of the future revenues of th'), preventing full comparison of the complete risk factor section
- Page numbers differ between filings (51-52 in newer vs. 61-62 in older), suggesting different document lengths or formatting
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 8 sells ($17M) — 2 selling insiders
- Last 180 days0 buys · 14 sells ($23M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-01. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about RPRX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
RPRX had 10,667,818 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for RPRX because the newest share count we hold predates that settlement by more than 180 days, and a buyback or issuance in between would move the base. The reported figures above are unaffected.
- Reported short interest (shares) 10,667,818
- Prior settlement (shares) 12,134,646
- Reported change -12.09%
- Days to cover (reported) 4.07
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- DRI Healthcare Trust (DHT.UN)
- Hayfin Capital Management
- Pharmakon Advisors
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Royalty Pharma is found in…
Frequently asked questions
What does Royalty Pharma (RPRX) do?
Royalty Pharma is a large-scale buyer of biopharmaceutical royalties, which acquires royalty interests in commercialized and development-stage medicines from academic institutions, research hospitals, non-profits, and biopharmaceutical companies. The company does not conduct internal drug development, instead acting as a capital provider that funds innovation in exchange for future revenue streams from life-science products.
What sector is Royalty Pharma (RPRX) in?
Royalty Pharma (RPRX) is classified in the Health Care sector. Its industry is Alternative Asset Management / Specialty Finance. It trades on NASDAQ.
Does RPRX pay a dividend?
Yes — Royalty Pharma (RPRX) pays a dividend, with an indicated yield of about 2.96% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Royalty Pharma's (RPRX) competitors?
Notable peers of Royalty Pharma (RPRX) include DRI Healthcare Trust, Hayfin Capital Management and Pharmakon Advisors. This peer set is informational only — not financial advice.
Is Royalty Pharma (RPRX) overbought or oversold right now?
Royalty Pharma (RPRX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on RPRX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.